Neogen Corp - Company Profile
Powered by 
All the sales intelligence you need on Neogen Corp in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Neogen Corp fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Neogen Corp.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
Neogen Corp (Neogen) develops, manufactures and markets various products related to food and animal safety. The company’s product portfolio includes diagnostic test kits to detect foodborne pathogens, natural toxins, spoilage organisms, food allergens, pesticide residues, genetic modifications, meat speciation, drug residues, ruminant by-products, animal safety, sanitation concerns and related products, pharmaceuticals, veterinary products, rodenticides, disinfectants, vaccines, topicals, cleaners, and insecticides. Neogen operates through a network of channel partners and distributors to reach its customers. The company also offers genetic testing services for animal safety. The company markets its products through various brands, including Neogen, Neogen flask, AccuScan, AccuPoint, AccuClean, Acumedia, Agri-Screen, Alert, ANSR, BetaStar, BioLumix, Centrus and others. Neogen and its subsidiaries operate across the world. Neogen is headquartered in Lansing, Michigan, the US.
Headquarters
United States of America
Address
620 Lesher Place, Lansing, Michigan, 48912
Website
www.neogen.com
Telephone
1 800 2345333
No of Employees
2,974
Industry
Medical Equipment
Ticker Symbol & Exchange
NEOG (NASD)
Revenue (2025)
$894.7M
-3.2%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
-11491.6%
(2025 vs 2024)
Market Cap*
$2.0B
Net Profit Margin (2025)
XYZ
-11,866.7%
(2025 vs 2024)
* As of and is in US$
Neogen Corp premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Diagnostics: | Neogen |
| Adulteration | Neogen flask |
| Allergens | AccuScan |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In March, the company signed a definitive agreement to sell its animal genomics business to Zoetis Inc., a animal health company for US$160 million. |
| 2026 | Product Recall | In January, the company recalled Neogen Vet HYCOAT Hyaluronate Sodium Sterile Solution due to microbial contamination found in some 10 mL/50 mg vials. |
| 2025 | Contracts/Agreements | In September, the company renewed its partnership with the US Equestrian Federation. |
Competitor Comparison
| Key Parameters | Neogen Corp | Thermo Fisher Scientific Inc | Elanco Animal Health Inc | Idexx Laboratories Inc | LGC Clinical Diagnostics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Lansing | Waltham | Greenfield | Westbrook | Milford |
| State/Province | Michigan | Massachusetts | Indiana | Maine | Massachusetts |
| No. of Employees | 2,974 | 125,000 | 9,000 | 11,000 | 30 |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| James C. Borel | Chairman | Executive Board | 2016 | 70 |
| Mike Nassif | President; Chief Executive Officer; Director | Executive Board | 2025 | 50 |
| Bryan Riggsbee | Chief Financial Officer | Senior Management | 2025 | - |
| John Moylan | Corporate Controller; Chief Accounting Officer; Vice President | Senior Management | 2024 | 59 |
| Jeremy Yarwood | Chief Scientific Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer